Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03512405 · ClinicalTrials.gov registry record · Phase 1

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

A Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT03512405 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 36 participants, below the 43-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03512405, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and Recurrent Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such as pembrolizumab and blinatumomab, may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Refractory Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia Philadelphia Chromosome Positive CD19 Positive

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Blinatumomab

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2019-08-02
Est. Completion 2025-11-11
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03512405

The ClinicalTrials.gov registry entry for NCT03512405 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (16% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Refractory Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03512405 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03512405 about?

NCT03512405 is a clinical study titled "Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia". This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such as pembrolizumab and blinatumomab, may interfere w...

What is the current status of trial NCT03512405?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-08-02. Estimated completion is 2025-11-11.

What conditions does trial NCT03512405 study?

This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive, CD19 Positive.

What interventions are being tested in trial NCT03512405?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Blinatumomab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03512405?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03512405 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Acute Lymphoblastic Leukemia

All registered trials for this condition

Recurrent Acute Lymphoblastic Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.